Metraipolis › archive › dc_7e8771418316

CRISPR Genome Editing and the Future of Leukaemia Immunotherapy — Europe PMC PMID:42110387

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42110387
DOI
10.1002/hsr2.72497
License (as archived)
solo-consultazione
Archived
2026-11-02T17:52:29.832Z
SHA-256 of the archived text
ab97b27b758049d70a71a6ab21892104117720ed635b6fed49b5aaf67122c161
Stable URL of this page
https://metraipolis.com/documento/dc_7e8771418316

How to cite

CRISPR Genome Editing and the Future of Leukaemia Immunotherapy — Europe PMC PMID:42110387 — Europe PMC (en), https://europepmc.org/article/MED/42110387 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7e8771418316 (Metraipolis archive dc_7e8771418316, sha256 ab97b27b758049d70a71a6ab21892104117720ed635b6fed49b5aaf67122c161)
BibTeX
@misc{dc7e8771418316,
  title = {CRISPR Genome Editing and the Future of Leukaemia Immunotherapy — Europe PMC PMID:42110387},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42110387},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7e8771418316; sha256 ab97b27b758049d70a71a6ab21892104117720ed635b6fed49b5aaf67122c161},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42110387. Agents can read the archived copy with the MCP tool read_document.